CORPORATE & U.S. HEADQUARTERSNew York
10 Hudson Yards, 37th Floor | New York, NY 10001 | T: 646-747-1000
RESEARCH & DEVELOPMENT HEADQUARTERSSan Diego
9520 Towne Centre Drive, Suite 200 | San Diego, CA 92121 | T: 858-652-6800
INTERNATIONAL HEADQUARTERSLondon
Two Pancras Square | Kings Cross, London,
N1C 4AG, UK | T:+44 203 805 7600
Austria
Fleischmarkt 1/6/12
A-1010 Vienna, Austria
T: +43 1 20 5107 3106
E: info-AT@interceptpharma.com
Canada
4263 Sherwoodtowne Blvd, Suite 300
Mississauga, ON
L5B 3C3
T: +1 877-559-ICPT (4278)
E: Info-Canada@Interceptpharma.com
France
Paris Madeleine
19, Boulevard Malesherbes
75008 Paris, France
T: +33 1 55 27 39 16
E: Interceptfrance@interceptpharma.com
Germany
Rosenheimer Str. 52
D-81669 München, Germany
T: +49 89 4111 124 11
E: info-DE@interceptpharma.com
Ireland
Ormond Building
31-36 Ormond Quay Upper, Dublin 7, Dublin, Republic of Ireland
T: +353 15274019
E: info-Ireland@interceptpharma.com
Italy
Via Giosuè Carducci 24
20123 Milano, Italy
T: +39 02 66661030
E: info.italia@interceptpharma.com
Luxembourg
Paris Madeleine
19, Boulevard Malesherbes
75008 Paris, France
T: +33 1 55 27 39 16
E: Interceptfrance@interceptpharma.com
Portugal
Centro Empresarial Torres de Lisboa
Rua Tomás da Fonseca, Torre G, 1º Piso
1600-209 Lisboa
Portugal
T: +351 21 723 0729 or +351 21 723 0731
E: geral.pt@interceptpharma.com
Switzerland
City Center Stockerhof
Dreikönigstrasse 31A
8002 Zürich, Switzerland
T: +41 (0)44 208 3616
F: +41 (0)44 208 3500
E: info-CH@interceptpharma.com
United Kingdom
Two Pancras Square
Kings Cross, London, N1C 4AG, UK
T: +44 203 805 7600
E: info-UK@interceptpharma.com
Additional transparency disclosures
Since March 2018, Intercept has partnered with AOP Orphan Pharmaceuticals AG (HQ Vienna, Austria) in a number of European countries where Intercept does not have a direct affiliate presence. Although Intercept retains the Marketing Authorisation across Europe, AOP takes full commercialisation responsibility of OCALIVA in these countries.
Intercept is committed to ensuring transparency around interactions with Healthcare Professionals, Healthcare Organizations and Patient Organizations in line with legal and code obligations. The below links provide transparency disclosure information in these countries as they relate to Intercept: